CN1856323B - 在癌症治疗中用于抑制多药耐药性的靶向p-糖蛋白170的治疗性疫苗 - Google Patents

在癌症治疗中用于抑制多药耐药性的靶向p-糖蛋白170的治疗性疫苗 Download PDF

Info

Publication number
CN1856323B
CN1856323B CN2004800274241A CN200480027424A CN1856323B CN 1856323 B CN1856323 B CN 1856323B CN 2004800274241 A CN2004800274241 A CN 2004800274241A CN 200480027424 A CN200480027424 A CN 200480027424A CN 1856323 B CN1856323 B CN 1856323B
Authority
CN
China
Prior art keywords
seq
immunogenic composition
peptide
antibody
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800274241A
Other languages
English (en)
Chinese (zh)
Other versions
CN1856323A (zh
Inventor
P·F·托西
C·马杜莱特
C·尼古劳
D·T·希客曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
AC Immune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AC Immune SA filed Critical AC Immune SA
Publication of CN1856323A publication Critical patent/CN1856323A/zh
Application granted granted Critical
Publication of CN1856323B publication Critical patent/CN1856323B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
CN2004800274241A 2003-07-25 2004-07-25 在癌症治疗中用于抑制多药耐药性的靶向p-糖蛋白170的治疗性疫苗 Expired - Fee Related CN1856323B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0309188 2003-07-25
FR0309188A FR2857875A1 (fr) 2003-07-25 2003-07-25 Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers
PCT/EP2004/008330 WO2005014036A1 (fr) 2003-07-25 2004-07-25 Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers

Publications (2)

Publication Number Publication Date
CN1856323A CN1856323A (zh) 2006-11-01
CN1856323B true CN1856323B (zh) 2013-12-25

Family

ID=33561147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800274241A Expired - Fee Related CN1856323B (zh) 2003-07-25 2004-07-25 在癌症治疗中用于抑制多药耐药性的靶向p-糖蛋白170的治疗性疫苗

Country Status (9)

Country Link
US (1) US20060233758A1 (enExample)
EP (2) EP2316478B1 (enExample)
JP (2) JP2006528650A (enExample)
KR (2) KR20060125676A (enExample)
CN (1) CN1856323B (enExample)
AU (1) AU2004262472B2 (enExample)
CA (1) CA2533540C (enExample)
FR (1) FR2857875A1 (enExample)
WO (1) WO2005014036A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20080026995A1 (en) * 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US7807171B2 (en) * 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US8090392B2 (en) * 2005-08-05 2012-01-03 Interdigital Technology Corporation Method and system for reporting a short message capability via an IP multimedia subsystem
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
KR101130754B1 (ko) * 2010-06-25 2012-03-28 제일약품주식회사 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
WO2012055933A1 (en) 2010-10-26 2012-05-03 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
CN112687354B (zh) * 2019-01-29 2022-07-12 杭州纽安津生物科技有限公司 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法
CN113648429B (zh) * 2021-07-06 2023-11-10 中山大学 靶向肿瘤周围细胞激活免疫的聚合物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
EP0669941A1 (en) * 1992-11-02 1995-09-06 NICOLAU, Yves Claude Method of reducing multidrug resistance in cells and tissues
JP3759759B2 (ja) * 1994-03-04 2006-03-29 日本油脂株式会社 リポソームおよび薬物運搬体
JP4385152B2 (ja) * 1997-09-17 2009-12-16 三菱化学株式会社 ２価反応性水溶性高分子誘導体及びそれを含有する複合体
JP2002047298A (ja) * 2000-07-10 2002-02-12 Academia Sinica 新規抗がん剤伝達系
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
BRPI0411166A (pt) * 2003-05-12 2006-07-18 Affymax Inc composto compreendendo uma parcela de peptìdeo, uma parcela espaçadora e uma parcela de polìmero solúvel em água e composição farmacêutica compreendendo tal composto

Also Published As

Publication number Publication date
EP1651257A1 (fr) 2006-05-03
FR2857875A1 (fr) 2005-01-28
KR20060125676A (ko) 2006-12-06
EP2316478A1 (fr) 2011-05-04
EP1651257B1 (fr) 2016-02-17
CA2533540C (fr) 2016-02-23
AU2004262472A2 (en) 2005-02-17
KR20130008092A (ko) 2013-01-21
AU2004262472B2 (en) 2011-07-14
US20060233758A1 (en) 2006-10-19
JP2013121977A (ja) 2013-06-20
CA2533540A1 (fr) 2005-02-17
JP2006528650A (ja) 2006-12-21
WO2005014036A1 (fr) 2005-02-17
EP2316478B1 (fr) 2017-04-26
AU2004262472A1 (en) 2005-02-17
CN1856323A (zh) 2006-11-01

Similar Documents

Publication Publication Date Title
US8409580B2 (en) Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
JP2013121977A (ja) 癌の治療における多剤耐性を抑制するための、ｐ−糖タンパク質１７０を標的とする治療ワクチン
KR101208173B1 (ko) 초분자 구조체를 포함하는 방법 및 조성물
JP3839483B2 (ja) コレステリルエステル転移タンパク質（ｃｅｔｐ）活性の調節
EP1204423B1 (en) Therapeutic antibody against muc-1 antigen and methods for their use
JP5519477B2 (ja) Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US6238667B1 (en) Method of affinity cross-linking biologically active immunogenic peptides to antibodies
US20040052809A1 (en) Vaccine
US12280109B2 (en) Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
US20080026995A1 (en) Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US20050244419A1 (en) Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
Pawlak-Roblin et al. Inhibition of multidrug resistance by immunisation with synthetic P-glycoprotein-derived peptides
US20050255561A1 (en) Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2004080375A2 (en) Vaccine therapy of atherosclerosis
JP7585480B2 (ja) Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
HK1096577A (en) Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096577

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131225

Termination date: 20190725